All times are listed in CEST (Central European Summer Time)
LBA32 - Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
- Susana Banerjee (London, United Kingdom)
Abstract
Background
Anti-PD-1/L1 therapy alone has limited activity in ovarian cancer. We hypothesised that blockade of VEGF and prostaglandin E2 (PGE2) can reverse the endothelial barrier allowing T cell infiltration and subsequent T cell activation by PD-L1 blockade. This is the first trial combining an anti-PD-L1 antibody, atezolizumab (ATE), with bevacizumab (BEV) and the irreversible COX1/2 inhibitor acetylsalicylic acid (ASA).
Methods
Patients with platinum-resistant ovarian cancer (PROC) were randomised to 1) BEV(15mg/kg q3w) 2) ATE(1200mg q3w)+placebo(P) 3) ATE(1200mg q3w)+ASA(320mg/d) 4) BEV(15mg/kg q3w)+ATE(1200mg q3w)+P or 5) BEV(15mg/kg q3w)+ATE(1200mg q3w)+ASA(320mg/d) and treated until progression or unacceptable toxicity. Arms 2 and 3 were closed early following phase III results indicating insufficient activity of PD-L1 inhibitor monotherapy. Mandatory biopsies (pre-treatment and pre-cycle 3) and serial blood samples were collected. The primary endpoint was progression-free survival rate at 6 months (PFS-6). Secondary endpoints included tolerability, PFS, response rate (RR) and time to first subsequent therapy (TFST).
Results
122 patients were randomised: BEV(33); ATE+P(11); ATE+ASA(13); BEV+ATE+P(32); BEV+ATE+ASA(33). Median age 63 (36-82); 84% ≥3 prior therapies. 39/52 (75%) patients treated (Arms 1-3) crossed over at progression to BEV+ATE. PFS-6 rates (ITT) were 22%, 9%, 23%, 25% and 25% respectively. Median PFS were 2.3, 2.1 (HR 1.78, 0.89-3.58); 2.2 (HR 0.95, 0.49-1.85), 4.1 (0.84, 0.50-1.38), and 4.0 months (0.81, 0.49-1.34). RR: 10%, 0%, 9%, 19% and 15% respectively. Median TFST was longest in BEV+ATE containing arms (3.0, 2.4, 1.8, 5.3 and 5.8 months; P<0.001). Grade 3/4 treatment-related adverse events were 48%,10%, 36%, 32% and 30% respectively.
Conclusions
The addition of ASA to BEV+ATE did not improve efficacy. Relative to BEV or ATE(+/-ASA) arms, the BEV+ATE combinations numerically improved PFS and TFST and merits further exploration. Translational analyses are ongoing to identify biomarkers of clinical benefit.
Clinical trial identification
EudraCT 2015-004601-17 / NCT02659384.
Legal entity responsible for the study
European Organisation for Research and Treatment of Cancer - EORTC.
Funding
EORTC with support from F. Hoffmann-La Roche Ltd.
Disclosure
S. Banerjee: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Seattle Genetics; Financial Interests, Personal, Invited Speaker: Clovis; Financial Interests, Personal, Advisory Board: Genmab; Financial Interests, Personal, Advisory Board: Immunogen; Financial Interests, Personal, Advisory Board: Mersana; Financial Interests, Personal, Advisory Board: Merck Sereno; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Tesaro; Financial Interests, Personal, Invited Speaker: Tesaro; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: GSK; Financial Interests, Institutional, Research Grant: Tesaro; Non-Financial Interests, Principal Investigator, Phase II clinical trial Global lead: Verastem; Non-Financial Interests, Principal Investigator, ATARI phase II international trial (academic sponsored): Astrazeneca; Non-Financial Interests, Advisory Role: Epsilogen; Non-Financial Interests, Other, Member of membership committee: ESGO; Non-Financial Interests, Advisory Role, Medical advisor to UK ovarian cancer charity: Ovacome Charity; Non-Financial Interests, Other, Received research funding from UK based charity I have provided medical advice (non-remunerated): Lady Garden Foundation Charity. P.B. Ottevanger: Financial Interests, Institutional, Research Grant: Pharmamar. A. Sarivalasis: Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: GSK; Financial Interests, Personal, Advisory Role: Tesaro; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Institutional, Research Grant: Roche. J.R. Kroep: Financial Interests, Personal, Advisory Role: VitroScan. L. Kandalaft: Financial Interests, Personal, Advisory Board: Geneos. G. Coukos: Financial Interests, Institutional, Research Grant: Celgene; Financial Interests, Institutional, Research Grant: Boehringer-Ingelheim; Financial Interests, Personal, Advisory Role: Genentech; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Institutional, Research Grant: Iovance; Financial Interests, Institutional, Research Grant: Kite Pharma; Financial Interests, Personal, Advisory Role: NextCure; Financial Interests, Personal, Advisory Role: Sanofi. All other authors have declared no conflicts of interest.
721O - Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study
- Domenica Lorusso (Rome, Italy)
Abstract
Background
Pre-clinical and clinical data indicate that glucocorticoid receptor (GR) antagonism may enhance/restore chemotherapy sensitivity. This is the first randomized, controlled study to explore the efficacy and safety of relacorilant (RELA), a selective GR modulator, in combination w/ nab-paclitaxel (nab-pac) compared to nab-pac alone.
Methods
Women w/ recurrent platinum-resistant/refractory high grade serous or endometroid epithelial ovarian, primary peritoneal, or fallopian tube cancer or ovarian carcinosarcoma w/ measurable or non-measurable disease and up to 4 chemotherapeutic regimens were 1:1:1 randomized to: -CONTINUOUS 100mg RELA daily (w/discretionary escalation to 150mg) + 80mg/m2 nab-pac on days 1, 8, and 15 of a q28-day schedule; or -INTERMITTENT 150mg RELA the day before, of, and after 80mg/m2 nab-pac on days 1, 8, and 15, of a q28-day schedule; or -COMPARATOR,100mg/m2 nab-pac on days 1, 8, and 15, of a q28-day schedule. A lower nab-pac dose was used with RELA because RELA inhibits the metabolism of nab-pac. The primary endpoint was progression-free survival (PFS) determined by the investigator per RECIST 1.1.
Results
178 women were randomized. At median follow-up of 11.07 mos, the INTERMITTENT regimen significantly improved median PFS compared to nab-pac alone (HR, 0.66, 95%CI 0.44-0.98, log-rank test p=0.038). While ORR was similar, Duration of Response (DoR) was significantly improved (HR 0.36, 95% 0.16-0.77, p=0.006) in the INTERMITTENT regimen vs. nab-pac alone. Overall survival will be assessed at maturity. Most common grade ≥3 adverse events were neutropenia, anemia, and peripheral sensory neuropathy.
5.29 (3.84, 5.55) 5.55* (3.68, 7.20) 3.76 (3.52, 5.36) n=19 35.2 (22.68, 49.38) n=20 35.7 (23.36, 49.64) n=19 35.8 (23.14, 50.20) 3.79 (2.33, 5.55) 5.55** (3.75, 5.88) 3.65 (2.89, 5.09) *P<0.05 vs. Nab-Pac alone **P<0.01 vs. Nab-Pac alone n=57 n=60 n=60 Neutropenia 14 (24.6%) 4 (6.7%) 8 (13.3%) Anemia 11 (19.3%) 8 (13.3%) 7 (11.7%) Peripheral Sensory Neuropathy 9 (15.8%) 0 (0%) 3 (5.0%) TEAEs=Treatment-Emergent Adverse Events
Conclusions
INTERMITTENT RELA + nab-pac improved PFS and had a favorable safety profile in recurrent platinum-resistant and/or platinum-refractory ovarian cancer patients.
Clinical trial identification
NCT03776812.
Legal entity responsible for the study
Corcept Therapeutics.
Funding
Corcept Therapeutics.
Disclosure
N. Colombo: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Principal Investigator: AstraZeneca; Financial Interests, Personal, Advisory Board: Clovis; Financial Interests, Personal, Speaker’s Bureau: Clovis; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Speaker’s Bureau: MSD; Financial Interests, Personal, Speaker’s Bureau: GSK; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Immunogen; Financial Interests, Personal, Advisory Board: Mersana; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: Oncxe; Financial Interests, Personal, Speaker’s Bureau, Corcept Therapeutics: Novartis; Financial Interests, Personal, Principal Investigator: Corcept Therapeutics. D.D. Nguyen: Financial Interests, Personal, Full or part-time Employment: Corcept Therapeutics. G.F. Fleming: Financial Interests, Personal, Principal Investigator: Corcept Therapeutics; Financial Interests, Personal, Principal Investigator: Roche; Financial Interests, Personal, Principal Investigator: Syros; Financial Interests, Personal, Principal Investigator: GSK; Financial Interests, Personal, Principal Investigator: Iovance; Financial Interests, Personal, Principal Investigator: Sermonix; Financial Interests, Personal, Principal Investigator: Compugen; Financial Interests, Personal, Principal Investigator: Celldex; Financial Interests, Personal, Principal Investigator: Plexxicon; Financial Interests, Personal, Principal Investigator: AstraZeneca. R.N. Grisham: Financial Interests, Personal, Advisory Board: Signatera; Financial Interests, Personal, Advisory Board: Verastem; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: PER; Financial Interests, Personal, Advisory Board: Aptitude; Financial Interests, Personal, Principal Investigator: Corcept Therapeutics; Financial Interests, Personal, Principal Investigator: Context; Financial Interests, Personal, Principal Investigator: Verastem; Financial Interests, Personal, Principal Investigator: Bayer; Financial Interests, Personal, Principal Investigator: Pfizer; Financial Interests, Personal, Principal Investigator: Novartis. D. Lorusso: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Principal Investigator: AstraZeneca; Financial Interests, Personal, Other, Travel Grant: AstraZeneca; Financial Interests, Personal, Advisory Board: Clovis; Financial Interests, Personal, Speaker’s Bureau: Clovis; Financial Interests, Personal, Principal Investigator: Clovis; Financial Interests, Personal, Principal Investigator: Corcept Therapeutics; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Speaker’s Bureau: GSK; Financial Interests, Personal, Principal Investigator: GSK; Financial Interests, Personal, Other, Travel Grant: GSK; Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Principal Investigator: MSD; Financial Interests, Personal, Advisory Board: Pharmamar; Financial Interests, Personal, Principal Investigator: Immonogen; Financial Interests, Personal, Principal Investigator: Genmab; Financial Interests, Personal, Other, Travel Grant: Roche. T. Van Gorp: Financial Interests, Institutional, Advisory Board: MSD; Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Institutional, Advisory Board: OncXerna; Financial Interests, Institutional, Advisory Board: Eisai; Financial Interests, Institutional, Principal Investigator: Amgen; Financial Interests, Institutional, Principal Investigator: Roche; Financial Interests, Institutional, Principal Investigator: Corcept Therapeutics. A. Oaknin: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: PharmaMar; Financial Interests, Personal, Advisory Board: Clovis; Financial Interests, Personal, Advisory Board: Tesaro; Financial Interests, Personal, Advisory Board: Immunogen; Financial Interests, Personal, Advisory Board: Genmab; Financial Interests, Personal, Advisory Board: Mersana; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: Deciphera; Financial Interests, Institutional, Principal Investigator: Abbvie Deutschland; Financial Interests, Institutional, Principal Investigator: Ability; Financial Interests, Institutional, Principal Investigator: Advaxis; Financial Interests, Institutional, Principal Investigator: Aeterna Zentaris. H.I. Pashova: Financial Interests, Personal, Full or part-time Employment: Corcept Therapeutics. A. Grauer: Financial Interests, Personal, Full or part-time Employment: Corcept Therapeutics.
Invited Discussant LBA32 and 721O
- Rosalind M. Glasspool (Glasgow, United Kingdom)
Q&A and live discussion
- Rosalind M. Glasspool (Glasgow, United Kingdom)
722O - Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)
- Shibani Nicum (Oxford, United Kingdom)
Abstract
Background
The main aims of the OCTOVA trial were to compare the efficacy and toxicity of olaparib (O) with weekly paclitaxel (wP) and also the oral combination of olaparib plus cediranib (O+C) in recurrent ovarian cancer (OC).
Methods
Participants with high grade ovarian, fallopian tube, primary peritoneal cancer who relapsed within 12 months of previous platinum-based therapy were randomised, with stratification for germline
Results
OCTOVA recruited 139 participants, median 65 years (IQR:38-84), from 15 UK centres over 34 months. 31 (22%) had had prior PARPi therapy, 47 (34%) prior anti-angiogenic therapy. 41 (29%) had known germline
Conclusions
The OCTOVA trial demonstrated that the combination of O+C showed greater efficacy than O alone, but we did not find evidence that wP was inferior to O in women with multiply relapsed OC.
Clinical trial identification
ISRCTN14784018, NCT03117933.
Legal entity responsible for the study
University of Oxford.
Funding
AstraZeneca.
Disclosure
S. Nicum: Financial Interests, Other, Advisory and speaker honoraria, travel expenses: GSK; Financial Interests, Other, Advisory and speaker honoraria, travel expenses: Tesaro; Financial Interests, Other, Advisory and speaker honoraria, travel expenses: Roche; Financial Interests, Other, Advisory and speaker honoraria: Abbvie; Financial Interests, Other, Advisory and speaker honoraria: Clovis; Financial Interests, Other, Advisory and speaker honoraria, travel expenses and peer-reviewed research funding: AstraZeneca. I. McNeish: Financial Interests, Advisory Board, Advisory Board and institutional funding: AstraZeneca; Financial Interests, Advisory Board: GSK; Financial Interests, Advisory Board: Clovis Oncology; Financial Interests, Advisory Board: Roche; Financial Interests, Advisory Board: Scancell. R.M. Glasspool: Financial Interests, Advisory Board, Advisory boards speaker fees: AstraZeneca; Financial Interests, Advisory Board: MSD; Financial Interests, Advisory Board, Advisory boards speaker fees: Clovis; Financial Interests, Advisory Board, Advisory boards speaker fees: GSK/Tesaro; Financial Interests, Other, Consultacy fees: Sotio; Financial Interests, Advisory Board: Immunogen; Financial Interests, Research Grant, Investigator Initiated Trial Grant: Clovis; Financial Interests, Principal Investigator, Site PI for commercially sponsored trials: Clovis; Financial Interests, Principal Investigator, Site PI for commercially sponsored trials: AstraZeneca; Financial Interests, Principal Investigator, Site PI for commercially sponsored trials: GSK; Financial Interests, Principal Investigator, Site PI for commercially sponsored trials: Immunogen; Financial Interests, Research Grant, Investigator Initiated Trial Grant: Boehringer Ingelheim; Financial Interests, Research Grant, Investigator Initiated Trial Grant: Lilly/Ignyta; Financial Interests, Principal Investigator, Site PI for commercially sponsored trials: Lilly/Ignyta; Financial Interests, Other, Consultacy fees for trial streeing committee: Novartis; Financial Interests, Leadership Role: NCRI Ovarian Group Chair; Financial Interests, Leadership Role: SGCTG Ovarian lead; Financial Interests, Leadership Role: IGCS council member; Financial Interests, Leadership Role: ESMO Gyn Cancer Faculty; Financial Interests, Leadership Role: GCIG Meta-Analysis Group Chair; Financial Interests, Leadership Role: ENGOT early phase Co-Chair; Financial Interests, Leadership Role: Horizons Study Expert Panel member; Financial Interests, Leadership Role: Target Ovarian Cancer Scientific Advisory Board. M. Hall: Financial Interests, Research Grant, Clinical Trial grants: BMS; Financial Interests, Research Grant, Clinical Trial grants: Merck; Financial Interests, Invited Speaker, grants and personal fees: Clovis Oncology; Financial Interests, Invited Speaker, personal fees for Advisory Boards and educational roles GSK; Financial Interests, Invited Speaker, personal fees for Advisory Boards and educational roles: Amgen; Financial Interests, Invited Speaker, personal fees for Advisory Boards and educational roles: Roche; Financial Interests, Invited Speaker, personal fees for Advisory Boards and educational roles: AstraZeneca. A. Michael: Financial Interests, Advisory Board: Clovis; Financial Interests, Advisory Board: ESAI; Financial Interests, Advisory Board: Ipsen; Financial Interests, Advisory Board: Roche; Financial Interests, Advisory Board: Tesaro; Financial Interests, Advisory Board: GSK. S. Banerjee: Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Tesaro; Financial Interests, Institutional, Research Grant: GSK; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Genmab; Financial Interests, Personal, Advisory Board: Immunogen; Financial Interests, Personal, Advisory Board: Mersana; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Advisory Board: Oncxerna; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Clovis; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Invited Speaker: Takeda. G. Jayson: Financial Interests, Institutional, Research Grant: AstraZeneca. A. Clamp: Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Personal, Advisory Board: AstraZeneca. All other authors have declared no conflicts of interest.
LBA33 - Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
- Eric Pujade-Lauraine (Paris, CEDEX 4, France)
Abstract
Background
OReO/ENGOT Ov-38 (NCT03106987), a randomized, double-blind trial, is the first Phase III study to evaluate PARPi maintenance rechallenge.
Methods
Pts had non-mucinous platinum-sensitive relapsed (PSR) OC, one prior line of PARPi maintenance and were in response to their most recent platinum-based chemotherapy (PBC). Pts enrolled in BRCA1/2 mutated (BRCAm) (≥18 months [m] first-line [1L] or ≥12 m 2L+ prior PARPi exposure [PPE]) and non-BRCAm (≥12 m 1L or 6 m 2L+ PPE) cohorts were randomized (2:1; stratified by prior bevacizumab [yes vs no] and prior lines of PBC [≤3 vs ≥4]) to olaparib (O) tablets (300 mg bid [or 250 if 300 not previously tolerated]) or placebo (P) until progression. Primary endpoint was investigator-assessed progression-free survival (PFS; RECIST v1.1).
Results
112 pts were randomized in the BRCAm cohort (O: n=74; P: n=38); 108 in the non-BRCAm cohort (O: n=72; P: n=36). Pts were heavily pre-treated with 93% (BRCAm) and 86% (non-BRCAm) receiving ≥3 prior lines of any chemotherapy (see the table for other baseline characteristics). In the BRCAm cohort median PFS was 4.3 (O) vs 2.8 (P) m (hazard ratio [HR] 0.57; 95% CI 0.37–0.87; *Previously documented gBRCAm or sBRCAm by local testing. †gBRCAm negative by local testing; may include pts with undetected sBRCAm. ‡GIS ≥42 and/or a qualifying tBRCAm based on retrospective tumour testing (Myriad myChoice CDx); §GIS <42 and no qualifying tBRCAm. BRCAm,
BRCAm* Non-BRCAm† O N=74 P N=38 O N=72 P N=36 58.5 61.5 66.5 62.5 ≤3 64 61 65 67 ≥4 36 39 35 33 Complete 20 34 26 31 Partial 78 66 74 69 Missing 1 0 0 0 21.2 18.3 12.6 12.4 HRD+‡ ‒ ‒ 40 44 HRD−§ ‒ ‒ 42 31
Conclusions
The OReO/ENGOT Ov-38 trial is the first to provide data on PARPi rechallenge in PSR OC pts. The trial met its primary PFS endpoint. Maintenance O provided a significant improvement in PFS vs P, irrespective of BRCAm status. A proportion of pts derived clinically relevant long-term benefit. Safety was consistent with the known profile of O.
Clinical trial identification
NCT03106987.
Editorial acknowledgement
Medical writing assistance was provided by Elin Pyke, MChem, of Cence, funded by AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
AstraZeneca.
Funding
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
E. Pujade-Lauraine: Financial Interests, Personal, Invited Speaker: AstraZeneca, Tesaro, and Roche; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Tesaro, and Roche; Financial Interests, Personal, Other, Travel: AstraZeneca, Tesaro, and Roche; Financial Interests, Personal, Invited Speaker: Clovis Oncology, Incyte, and Pfizer; Financial Interests, Personal, Full or part-time Employment: ARCAGY Research. F. Selle: Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK-Tesaro, MSD, Sandoz (Novartis), Clovis Oncology; Financial Interests, Institutional, Research Grant: Roche, GSK-Tesaro, AstraZeneca, Immunogen, MSD, Incyte, Agenus. G. Scambia: Financial Interests, Personal, Speaker’s Bureau: Clovis Oncology Italy Srl and MSD Italia Srl. B. Asselain: Financial Interests, Personal, Other, Honoraria: BMS, AstraZeneca, Roche, Daiichi, Servier, and Pierre Fabre. F. Marmé: Financial Interests, Personal, Other, Honoraria: AstraZeneca, GSK/Tesaro, Clovis, MSD, Novartis, Pfizer, Lilly, Roche, Gilead/Immunomedics, Eisai, Celgene, GenicHealth and Myriad Genetics; Financial Interests, Personal, Advisory Board, Consulting: AstraZeneca, GSK/Tesaro, Clovis, MSD, Novartis, Pfizer, Lilly, Roche, Gilead/Immunomedics, Amgen, Eisai, Celgene, PharmaMar, Janssen-Cilag, GenicHealth, Myriad Genetics and Seagen; Financial Interests, Personal, Research Grant: AstraZeneca, GSK/Tesaro, Clovis, MSD, Novartis, Pfizer, Roche, Gilead/Immunomedics, PharmaMar, GBG and AGO Studiengruppe. K. Lindemann: Financial Interests, Personal, Advisory Role: AstraZeneca, GSK and Eisai; Financial Interests, Personal, Research Grant: GSK. N. Colombo: Financial Interests, Personal, Other, Honoraria: Roche/Genentech, AstraZeneca, Tesaro and PharmaMar; Financial Interests, Personal, Advisory Board, Consulting: Roche/Genentech, PharmaMar, AstraZeneca, Clovis Oncology, Pfizer, MSD Oncology, Takeda, Tesaro, and BioCadand GSK. R. Madry: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche and GSK; Financial Interests, Personal, Funding: AstraZeneca, Roche and GSK. R.M. Glasspool: Non-Financial Interests, Personal, Principal Investigator: AstraZeneca, Clovis, GSK/Tesaro, Immunogen, AbbVie, Pfizer, Lilly and Novartis; Financial Interests, Personal, Funding: Clovis, Boehringer Ingelheim and Lilly/Ignyta; Financial Interests, Institutional, Funding: GSK/Tesaro; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Clovis, Tesaro, GSK, Immunogen and Sotio; Financial Interests, Institutional, Other, Consultancy fee: Novartis. A. Oaknin: Financial Interests, Personal, Other, Consultancy fees: Roche, AstraZeneca, MSD/Merck, PharmaMar, Clovis Oncology, Tesaro/GSK, Immunogen, Genmab, SUTRO and Deciphera. C. Zamagni: Financial Interests, Personal, Advisory Board: Roche, Eisai, Novartis, AstraZeneca, Pfizer, PharmaMar, Amgen, Tesaro, QuintilesIMS, Lilly, Celgene; Financial Interests, Personal, Other, Travel accommodation: Roche, Novartis, Pfizer, PharmaMar, Tesaro, PierreFabre, Istituto Gentili, Celgene; Financial Interests, Institutional, Research Grant: Roche, Novartis, AstraZeneca, Pfizer, SeattleGenetics, Tesaro, PierreFabre, Istituto Gentili, Takeda, TEVA, Medivation, AbbVie, Array BioPharma, Morphotek, Synthon,; Non-Financial Interests, Personal, Member: Europa Donna italy, Susan J Komen Emilia-Romagna, LOTO Onlus, Mamazone Sudtirol. F. Heitz: Financial Interests, Personal, Other, Travel grants: AstraZeneca, Tesaro and Roche; Financial Interests, Personal, Other, Honoraria: Clovis and PharmaMar; Financial Interests, Personal, Funding: AGO studygroup; Financial Interests, Personal, Advisory Board: AstraZeneca, GSK and Roche. L. Gladieff: Financial Interests, Personal, Other, Honoraria: AstraZeneca, Clovis Oncology, GSK, PharmaMar, Roche, and Tesaro; Financial Interests, Institutional, Other, Honoraria: Clovis Oncology, GSK, and MSD; Financial Interests, Personal, Advisory Board: AstraZeneca, Clovis Oncology, GSK, and Tesaro; Financial Interests, Personal, Funding: PharmaMar, Roche, and Tesaro. C. Blakeley: Financial Interests, Personal, Full or part-time Employment, Former employee: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. B. Shaw: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. I.L. Ray-Coquard: Financial Interests, Personal, Other, Honoraria: AbbVie, Agenus, Advaxis, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche, GSK, MSD, Deciphera, Mersena, Merck Sereno, Novartis, Amgen, Tesaro and Clovis; Financial Interests, Institutional, Other, Honoraria: GSK, MSD, Roche and BMS; Financial Interests, Personal, Advisory Board: AbbVie, Agenus, Advaxis, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche/Genentech, GSK, MSD, Deciphera, Mersena, Merck Sereno, Novartis, Amgen, Tesaro and Clovis; Financial Interests, Personal, Research Grant: MSD, Roche and BMS; Financial Interests, Institutional, Research Grant: MSD, Roche, BMS, Novartis, AstraZeneca and Merck Sereno; Financial Interests, Personal, Other, Travel grant: Roche, AstraZeneca and GSK. A. Redondo: Financial Interests, Personal, Other, Honoraria: MSD, AstraZeneca, Roche, GSK, Clovis, PharmaMar, Lilly, and Amgen; Financial Interests, Personal, Advisory Board, Consultancy fees: MSD, AstraZeneca, Roche, GSK, Clovis, PharmaMar, Lilly, and Amgen; Financial Interests, Institutional, Research Grant: Eisai, PharmaMar, and Roche; Financial Interests, Personal, Other, Travel grant: AstraZeneca, Tesaro, PharmaMar, and Roch; Financial Interests, Personal, Speaker’s Bureau: MSD, AstraZeneca, Roche, GSK, Clovis, and PharmaMar. All other authors have declared no conflicts of interest.
Invited Discussant 722O and LBA33
- Clare L. Scott (Parkville, Australia)
Q&A and live discussion
- Clare L. Scott (Parkville, Australia)